Edwards Lifesciences (EW) Tops Q1 EPS by 1c; Raises Outlook

Edwards Lifesciences (NYSE: EW) reported Q1 EPS of $0.62, $0.01 better than the analyst estimate of $0.61. Revenue for the quarter came in at $1.46 billion versus the consensus estimate of $1.39 billion.

GUIDANCE:

Edwards Lifesciences sees Q2 2023 EPS of $0.62-$0.68, versus the consensus of $0.63. Edwards Lifesciences sees Q2 2023 revenue of $1.48-1.56 billion, versus the consensus of $1.46 billion.

Edwards Lifesciences sees FY2023 EPS of $2.48-$2.60, versus the consensus of $2.52. Edwards Lifesciences sees FY2023 revenue of $5.6-6 billion, versus the consensus of $5.85 billion.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• BMO Capital Reiterates Market Perform Rating on Axalta Coating Systems (AXTA)
• LEEF Brands appoints Hirsh Jain to board as independent director